Isolation and In Vitro Characterization of a Bacteriophage Targeting Antibiotic-Resistant Helicobacter pylori

Mohseni, Yasaman Zahra; Elikaei, Ameneh; Attaran, Bahareh; Soltani, Mahsa

year 19, Issue 6 (November - December 2025) Iran J Med Microbiol 2025, 19(6): 388-401 | Back to browse issues page

Mendeley

Zotero

RefWorks

Mohseni Y Z, Elikaei A, Attaran B, Soltani M. Isolation and In Vitro Characterization of a Bacteriophage Targeting Antibiotic-Resistant Helicobacter pylori. Iran J Med Microbiol 2025; 19 (6) :388-401
URL: http://ijmm.ir/article-1-2592-en.html

Isolation and In Vitro Characterization of a Bacteriophage Targeting Antibiotic-Resistant Helicobacter pylori

Yasaman Zahra Mohseni¹

, Ameneh Elikaei²

, Bahareh Attaran¹

, Mahsa Soltani¹

1- Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran
2- Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran , a.elikaei@alzahra.ac.ir

Abstract: (580 Views)

Background and Aim: The high occurrence rate of antibiotic-resistant Helicobacter (H.) pylori has led to consideration of novel therapeutic approaches. This study aimed to isolate and characterize a bacteriophage against antibiotic-resistant strains of H. pylori isolates from gastric biopsies of patients.
Materials and Methods: Untreated wastewater was collected from Imam Hossein, Taleghani, and Mofid Children’s Hospitals and mixed together. The presence of bacteriophage was confirmed by double-layer agar technique. Transmission Electron Microscope (TEM) was used to determine the morphology of the isolated phage. In addition, stability tests were performed. The host range and multiplicity of infection (MOI) of bacteriophages were determined. Finally, the phage genome was extracted and its concentration was calculated using a Nanodrop spectrophotometer.
Results: TEM micrograph showed that the isolated phage belonged to the Caudoviricetes class and had Podoviridae-like morphology. It was effective against 9 clinical strains of H. pylori and the standard strain of Campylobacter jejuni. The optimal activity of this phage was at 37°C and pH 4 to 7. This phage was sensitive to chloroform, and was stable with increasing salt concentration. It was revealed that MOI=1 was optimal for this bacteriophage activity.
Conclusion: In conclusion, the isolated phage was effective against antibiotic-resistant strains of H. pylori isolates from gastric biopsies of patients. It can be considered a suitable candidate for further genomic and in vivo studies.

Keywords: Antibiotic Resistance, Campylobacter jejuni, Caudoviricetes, H. pylori, Phage Therapy, Podoviridae

Full-Text [PDF 1450 kb] (27 Downloads)

Type of Study: Original Research Article | Subject: Medical Virology
Received: 2025/09/9 | Accepted: 2025/11/19 | ePublished: 2025/12/29

References

1. Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22:e12405. [DOI:10.1111/hel.12405] [PMID]

2. Polk DB, Peek Jr RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403-14. [DOI:10.1038/nrc2857] [PMID] [PMCID]

3. Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-9. [DOI:10.1053/j.gastro.2017.04.022] [PMID]

4. Yan TL, Hu QD, Zhang Q, Li YM, Liang TB. National rates of H elicobacter pylori recurrence are significantly and inversely correlated with human development index. Aliment Pharmacol Ther. 2013;37(10):963-8. [DOI:10.1111/apt.12293] [PMID]

5. Soluri MF, Puccio S, Caredda G, Edomi P, D'Elios MM, Cianchi F, et al. Defining the Helicobacter pylori disease-specific antigenic repertoire. Front Microbiol. 2020;11:1551. [DOI:10.3389/fmicb.2020.01551] [PMID] [PMCID]

6. Oktem-Okullu S, Cekic-Kipritci Z, Kilic E, Seymen N, Mansur-Ozen N, Sezerman U, et al. Analysis of correlation between the seven important Helicobacter pylori (H. pylori) virulence factors and drug resistance in patients with gastritis. Gastroenterol Res Pract. 2020;2020(1):3956838. [DOI:10.1155/2020/3956838] [PMID] [PMCID]

7. Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4):e12386. [DOI:10.1111/hel.12386] [PMID] [PMCID]

8. Martínez LE, Hardcastle JM, Wang J, Pincus Z, Tsang J, Hoover TR, et al. H elicobacter pylori strains vary cell shape and flagellum number to maintain robust motility in viscous environments. Mol Microbiol. 2016;99(1):88-110. [DOI:10.1111/mmi.13218] [PMID] [PMCID]

9. Sycuro LK, Pincus Z, Gutierrez KD, Biboy J, Stern CA, Vollmer W, et al. Peptidoglycan crosslinking relaxation promotes Helicobacter pylori's helical shape and stomach colonization. Cell. 2010;141(5):822-33. [DOI:10.1016/j.cell.2010.03.046] [PMID] [PMCID]

10. Luo Q, Liu N, Pu S, Zhuang Z, Gong H, Zhang D. A review on the research progress on non-pharmacological therapy of Helicobacter pylori. Front Microbiol. 2023;14:1134254. [DOI:10.3389/fmicb.2023.1134254] [PMID] [PMCID]

11. Malfertheiner P, Mégraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30. [DOI:10.1136/gutjnl-2016-312288] [PMID] [PMCID]

12. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-82. [DOI:10.1053/j.gastro.2018.07.007] [PMID] [PMCID]

13. Lopes D, Nunes C, Martins MC, Sarmento B, Reis S. Eradication of Helicobacter pylori: past, present and future. J Control Release. 2014;189:169-86. [DOI:10.1016/j.jconrel.2014.06.020] [PMID]

14. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-27. [DOI:10.1016/S1473-3099(17)30753-3] [PMID] [PMCID]

15. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-4. [DOI:10.4161/bact.1.2.14590] [PMID] [PMCID]

16. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today. 2005;10(12):807-9. [DOI:10.1016/S1359-6446(05)03441-0] [PMID]

17. Brüssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev. 2004;68(3):560-602. [DOI:10.1128/MMBR.68.3.560-602.2004] [PMID] [PMCID]

18. Paterson S, Vogwill T, Buckling A, Benmayor R, Spiers AJ, Thomson NR, et al. Antagonistic coevolution accelerates molecular evolution. Nature. 2010;464(7286):275-8. [DOI:10.1038/nature08798] [PMID] [PMCID]

19. Touchon M, Bernheim A, Rocha EP. Genetic and life-history traits associated with the distribution of prophages in bacteria. ISME J. 2016;10(11):2744-54. [DOI:10.1038/ismej.2016.47] [PMID] [PMCID]

20. Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol. 2020;11:549084. [DOI:10.3389/fmicb.2020.549084] [PMID] [PMCID]

21. Uchiyama J, Takemura-Uchiyama I, Kato SI, Takeuchi H, Sakaguchi Y, Ujihara T, et al. Screening of KHP30-like prophages among Japanese Helicobacter pylori strains, and genetic analysis of a defective KHP30-like prophage sequence integrated in the genome of the H. pylori strain NY40. FEMS Microbiol Lett. 2016;363(16):fnw157. [DOI:10.1093/femsle/fnw157] [PMID]

22. Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:457104. [DOI:10.3389/fphar.2019.00513] [PMID] [PMCID]

23. Wei J, Peng N, Liang Y, Li K, Li Y. Phage therapy: consider the past, embrace the future. Appl Sci. 2020;10(21):7654. [DOI:10.3390/app10217654]

24. Attaran B, Falsafi T, Ghorbanmehr N. Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics. World J Gastroenterol. 2017;23(7):1163. [DOI:10.3748/wjg.v23.i7.1163] [PMID] [PMCID]

25. Jiang X, Doyle MP. Growth supplements for Helicobacter pylori. J Clin Microbiol. 2000;38(5):1984-7. [DOI:10.1128/JCM.38.5.1984-1987.2000] [PMID] [PMCID]

26. Al-Sulami AA, Al-Edani TA, Al-Abdula AA. Culture method and PCR for the detection of Helicobacter pylori in drinking water in Basrah Governorate Iraq. Gastroenterol Res Pract. 2012;2012(1):245167. [DOI:10.1155/2012/245167] [PMID] [PMCID]

27. Soleimani Sasani M, Eftekhar F. Potential of a bacteriophage isolated from wastewater in treatment of lobar pneumonia infection induced by Klebsiella pneumoniae in mice. Curr Microbiol. 2020;77(10):2650-5. [DOI:10.1007/s00284-020-02041-z] [PMID]

28. Shahin K, Bouzari M, Wang R. Isolation, characterization and genomic analysis of a novel lytic bacteriophage vB_SsoS-ISF002 infecting Shigella sonnei and Shigella flexneri. J Med Microbiol. 2018;67(3):376-86. [DOI:10.1099/jmm.0.000683] [PMID]

29. Ferreira R, Sousa C, Gonçalves RF, Pinheiro AC, Oleastro M, Wagemans J, et al. Characterization and genomic analysis of a new phage infecting Helicobacter pylori. Int J Mol Sci. 2022;23(14):7885. [DOI:10.3390/ijms23147885] [PMID] [PMCID]

30. Drulis-Kawa Z, Mackiewicz P, Kęsik-Szeloch A, Maciaszczyk-Dziubinska E, Weber-Dąbrowska B, Dorotkiewicz-Jach A, et al. Isolation and characterisation of KP34-a novel φKMV-like bacteriophage for Klebsiella pneumoniae. Appl Microbiol Biotechnol. 2011;90(4):1333-45. [DOI:10.1007/s00253-011-3149-y] [PMID] [PMCID]

31. Jamal M, Hussain T, Das CR, Andleeb S. Characterization of Siphoviridae phage Z and studying its efficacy against multidrug-resistant Klebsiella pneumoniae planktonic cells and biofilm. J Med Microbiol. 2015;64(4):454-62. [DOI:10.1099/jmm.0.000040] [PMID]

32. Necel A, Bloch S, Nejman-Faleńczyk B, Grabski M, Topka G, Dydecka A, et al. Characterization of a bacteriophage, vB_Eco4M-7, that effectively infects many Escherichia coli O157 strains. Sci Rep. 2020;10(1):3743. [DOI:10.1038/s41598-020-60568-4] [PMID] [PMCID]

33. Yazdi M, Bouzari M, Ghaemi EA, Shahin K. Isolation, characterization and genomic analysis of a novel bacteriophage VB_EcoS-Golestan infecting multidrug-resistant Escherichia coli isolated from urinary tract infection. Sci Rep. 2020;10(1):7690. [DOI:10.1038/s41598-020-63048-x] [PMID] [PMCID]

34. Esmaeili-Fard-Barzegar K, Najar-Peerayeh S, Fard RM, Bakhshi B. Lytic potential of a filamentous bacteriophage isolated from sewage water in Tehran on clinical carbapenem-resistant strains. Iran J Microbiol. 2022;14(5):705-11. [DOI:10.18502/ijm.v14i5.10966] [PMID] [PMCID]

35. Liu J, Gao S, Dong Y, Lu C, Liu Y. Isolation and characterization of bacteriophages against virulent Aeromonas hydrophila. BMC Microbiol. 2020;20(1):141. [DOI:10.1186/s12866-020-01811-w] [PMID] [PMCID]

36. Borges A. Phage DNA extraction with phenol-chloroform and digestion to single nucleosides. 2022. [DOI:10.17504/protocols.io.8epv5jrxnl1b/v1]

37. Silva YJ, Costa L, Pereira C, Mateus C, Cunha Â, Calado R, et al. Phage therapy as an approach to prevent Vibrio anguillarum infections in fish larvae production. PLoS One. 2014;9(12):e114197. [DOI:10.1371/journal.pone.0114197] [PMID] [PMCID]

38. Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of Helicobacter pylori infection: clinical features, treatment, and nutritional aspects. Diseases. 2021;9(4):66. [DOI:10.3390/diseases9040066] [PMID] [PMCID]

39. Dincă AL, Meliț LE, Mărginean CO. Old and new aspects of H. pylori-associated Inflammation and gastric cancer. Children. 2022;9(7):1083. [DOI:10.3390/children9071083] [PMID] [PMCID]

40. UUgwu MC, Shariff M, Nnajide CM, Beri K, Okezie UM, Iroha IR, et al. Phenotypic and molecular characterization of β‐lactamases among enterobacterial uropathogens in southeastern Nigeria. Can J Infect Dis Med Microbiol. 2020;2020(1):5843904. [DOI:10.1155/2020/5843904] [PMID] [PMCID]

41. Pulingam T, Parumasivam T, Gazzali AM, Sulaiman AM, Chee JY, Lakshmanan M, et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022;170:106103. [DOI:10.1016/j.ejps.2021.106103] [PMID] [PMCID]

42. Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol. 2022;48(3):376-96. [DOI:10.1080/1040841X.2021.1975643] [PMID]

43. Batinovic S, Wassef F, Knowler SA, Rice DT, Stanton CR, Rose J, et al. Bacteriophages in natural and artificial environments. Pathogens. 2019;8(3):100. [DOI:10.3390/pathogens8030100] [PMID] [PMCID]

44. Lehours P, Vale FF, Bjursell MK, Melefors O, Advani R, Glavas S, et al. Genome sequencing reveals a phage in Helicobacter pylori. MBio. 2011;2(6):10-128. [DOI:10.1128/mBio.00239-11] [PMID] [PMCID]

45. Luo CH, Chiou PY, Yang CY, Lin NT. Genome, integration, and transduction of a novel temperate phage of Helicobacter pylori. J Virol. 2012;86(16):8781-92. [DOI:10.1128/JVI.00446-12] [PMID] [PMCID]

46. Vale FF, Matos AP, Carvalho P, Vítor JM. Helicobacter pylori phage screening. Microsc Microanal. 2008;14(S3):150-1. [DOI:10.1017/S1431927608089721]

47. Abdel-Haliem ME, Askora A. Isolation and characterization of bacteriophages of Helicobacter pylori isolated from Egypt. Future Virol. 2013;8(8):821-6. [DOI:10.2217/fvl.13.58]

48. Cuomo P, Papaianni M, Fulgione A, Guerra F, Capparelli R, Medaglia C. An innovative approach to control H. pylori-induced persistent inflammation and colonization. Microorganisms. 2020;8(8):1214. [DOI:10.3390/microorganisms8081214] [PMID] [PMCID]

49. Turner D, Shkoporov AN, Lood C, Millard AD, Dutilh BE, Alfenas-Zerbini P, et al. Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Arch Virol. 2023;168(2):74. [DOI:10.1007/s00705-022-05694-2] [PMID] [PMCID]

50. Mirzaei MK, Eriksson H, Kasuga K, Haggård-Ljungquist E, Nilsson AS. Genomic, proteomic, morphological, and phylogenetic analyses of vB_EcoP_SU10, a podoviridae phage with C3 morphology. PLoS One. 2014;9(12):e116294. [DOI:10.1371/journal.pone.0116294] [PMID] [PMCID]

51. Mohammadian F, Rahmani HK, Bidarian B, Khoramian B. Isolation and evaluation of the efficacy of bacteriophages against multidrug-resistant (MDR), methicillin-resistant (MRSA) and biofilm-producing strains of Staphylococcus aureus recovered from bovine mastitis. BMC Vet. Res. 2022;18(1):406. [DOI:10.1186/s12917-022-03501-3] [PMID] [PMCID]

52. Myers J, Davis II J, Lollo M, Hudec G, Hyman P. More's the same-Multiple hosts do not select for broader host range phages. Viruses. 2023;15(2):518. [DOI:10.3390/v15020518] [PMID] [PMCID]

53. Uchiyama J, Takeuchi H, Kato SI, Gamoh K, Takemura-Uchiyama I, Ujihara T, et al. Characterization of Helicobacter pylori bacteriophage KHP30. Appl Environ Microbiol. 2013;79(10):3176-84. [DOI:10.1128/AEM.03530-12] [PMID] [PMCID]

54. Al-Mohammadi AR, El-Didamony G, Abd El Moneem MS, Elshorbagy IM, Askora A, Enan G. Isolation and characterization of lytic bacteriophages specific for Campylobacter jejuni and Campylobacter coli. Zoonotic Dis. 2022;2(2):59-72. [DOI:10.3390/zoonoticdis2020007]

55. Steffan SM, Shakeri G, Hammerl JA, Kehrenberg C, Peh E, Rohde M, et al. Isolation and characterization of group III Campylobacter jejuni-specific bacteriophages from Germany and their suitability for use in food production. Front Microbiol. 2021;12:761223. [DOI:10.3389/fmicb.2021.761223] [PMID] [PMCID]

56. Yin H, Li J, Huang H, Wang Y, Qian X, Ren J, et al. Microencapsulated phages show prolonged stability in gastrointestinal environments and high therapeutic efficiency to treat Escherichia coli O157: H7 infection. Vet Res. 2021;52(1):118. [DOI:10.1186/s13567-021-00991-1] [PMID] [PMCID]

57. S Sabzali S, Bouzari M. Isolation, identification and some characteristics of two lytic bacteriophages against Salmonella enterica serovar Paratyphi B and S. enterica serovar Typhimurium from various food sources. FEMS Microbiol Lett. 2021;368(7):fnab037. [DOI:10.1093/femsle/fnab037] [PMID]

58. Ahmadi M, Karimi Torshizi MA, Rahimi S, Dennehy JJ. Prophylactic bacteriophage administration more effective than post-infection administration in reducing Salmonella enterica serovar Enteritidis shedding in quail. Front Microbiol. 2016;7:1253. [DOI:10.3389/fmicb.2016.01253] [PMID] [PMCID]

59. Cieplak T, Soffer N, Sulakvelidze A, Nielsen DS. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota. Gut Microbes. 2018;9(5):391-9. [DOI:10.1080/19490976.2018.1447291] [PMID] [PMCID]

60. Li YK, Wu X, Chen H, Zhao YY, Shu M, Zhong C, et al. A bacteriophage JN02 infecting multidrug-resistant Shiga toxin-producing Escherichia coli: isolation, characterisation and application as a biocontrol agent in foods. Int J Food Sci Technol. 2021;56(9):4756-69. [DOI:10.1111/ijfs.15070]

61. Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol. 2013;62(10):1506-16. [DOI:10.1099/jmm.0.061028-0] [PMID]

62. Pires DP, Oliveira H, Melo LD, Sillankorva S, Azeredo J. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol. 2016;100(5):2141-51. [DOI:10.1007/s00253-015-7247-0] [PMID]